NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

院內感染疾病(HAI)治療藥市場:醫藥品分類·感染疾病類型·各地區 - 市場佔有率·市場規模·趨勢·產業分析·預測(2021年∼2028年)

Hospital Acquired Infections Therapeutic Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs); By Infection Type; By Regions; Segment Forecast, 2021 - 2028

出版商 Polaris Market Research 商品編碼 1004400
出版日期 內容資訊 英文 118 Pages
商品交期: 最快1-2個工作天內
價格
院內感染疾病(HAI)治療藥市場:醫藥品分類·感染疾病類型·各地區 - 市場佔有率·市場規模·趨勢·產業分析·預測(2021年∼2028年) Hospital Acquired Infections Therapeutic Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs); By Infection Type; By Regions; Segment Forecast, 2021 - 2028
出版日期: 2021年04月01日內容資訊: 英文 118 Pages
簡介

全球院內感染疾病(HAI)治療藥的市場規模在2028年之前預測將達到125億2,000萬美元。

對抗生素具有抗藥性的致命病原體增加推動了對治療醫院感染 (HAI) 的新藥的需求。許多參與醫院感染 (HAI) 藥物市場的公司都在不斷進行開發新藥的研發活動,以獲得競爭優勢。

本報告提供全球院內感染疾病(HAI)治療藥市場相關調查,提供市場概要,市場區隔·各地區的市場規模的變化與預測,市場推動要素·阻礙因素分析,市場機會,課題,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 報告概要
    • 調查目的
    • 市場規模
    • 假設
  • 相關利益者

第2章 摘要整理

  • 市場概況

第3章 調查手法

  • 概要
    • 資料探勘
  • 資料來源
    • 一級資訊來源
    • 二級資訊來源

第4章 市場洞察

  • 產業概述
  • 市場動態
    • 推動要素和機會
    • 阻礙因素與課題
  • 波特的五力分析
    • 供給企業談判力(中)
    • 新加入廠商者的威脅(低)
    • 買方議價能力(中)
    • 替代品的威脅(中)
    • 競爭企業間的敵對關係(高)
  • 大環境分析
  • 產業趨勢

第5章 院內感染疾病(HAI)治療藥市場:各醫藥品分類

  • 主要調查結果
  • 簡介
    • 市場規模:各醫藥品分類(實際成果值·預測值)
  • 抗菌藥
    • 細胞壁合成抑制劑
    • 蛋白質合成抑制劑
  • 抗病毒藥物
  • 抗真菌藥物

第6章 院內感染疾病(HAI)治療藥市場:各感染疾病類型

  • 主要調查結果
  • 簡介
    • 市場規模:各感染疾病類型(實際成果值·預測值)
  • 泌尿道感染
  • 人工呼吸器感染疾病
  • 手術部位感染疾病
  • 血液感染疾病
  • 其他

第7章 院內感染疾病(HAI)治療藥市場:各地區

  • 主要調查結果
  • 簡介
  • 北美
    • 市場規模:各市場區隔(實際成果值·預測值)
    • 美國
    • 加拿大
  • 歐洲
    • 市場規模:各市場區隔(實際成果值·預測值)
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 奧地利
  • 亞太地區
    • 市場規模:各市場區隔(實際成果值·預測值)
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
  • 中東·非洲
    • 市場規模:各市場區隔(實際成果值·預測值)
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 以色列
  • 南美
    • 市場規模:各市場區隔(實際成果值·預測值)
    • 墨西哥
    • 巴西
    • 阿根廷

第8章 競爭情形

  • 擴大·收購
  • 夥伴關係·合作·契約·展示會

第9章 企業簡介

  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bayer AG
  • GlaxoSmithKline Plc.
  • Daiichi Sankyo Company, Limited
  • AbbVie Inc.
  • Abbott Laboratories
  • Allergan Plc.
  • F. Hoffmann-La Roche Ltd
  • Basilea Pharmaceutica AG
目錄
Product Code: PM1866

The global hospital acquired infections therapeutic market size is expected to reach USD 12.52 billion by 2028 according to a new study by Polaris Market Research. The report "Hospital Acquired Infections Therapeutic Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial Drugs {Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, Others}, Antiviral Drugs, Antifungal Drugs); By Infection Type; By Regions; Segment Forecast, 2021 - 2028" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Rising tolerance towards antibiotics in lethal pathogens also induced the market demand for novel therapeutics for treating hospital acquired infections. The majority of players in the market for hospital acquired infections therapeutic are continuously involved in research & development activities to develop new drugs to gain a competitive advantage.

In this direction, in June 2019, Food & Drug Administration (FDA) approved Merck's Zerbaxa (ceftolozane and tazobactam) drug for the treatment of ventilator-associated infections in patients aged 18 years and older. This is expected to drive the market for hospital acquired infections therapeutic.

Over the past few decades, chronic diseases such as diabetes, heart-related ailments, and arthritis are rising at an alarming speed. As per the data published by International Agency for Research on Cancer (IARC), in 2018, reported around 18.1 million new cancer cases.

This has resulted in a rise in healthcare admissions and an increased possibility of getting an hospital acquired infection. Moreover, as per the data of the New York State Department of Health in November 2019, more than 40% of the adults in the state suffer from some form of chronic disorder, accounting for around 23% of all the hospitalizations.

Asia Pacific is expected to register a lucrative market growth rate over the hospital acquired infection therapeutic study period. This market growth for hospital acquired infection therapeutic is attributed to the rising prevalence of chronic diseases in developing nations with high disposable income, which had led to an increase in hospital admissions.

For instance, as per the market study done by Globocan, in 2018, there were 4,285,033 new cancer cases in China. Thus, with increased hospital admissions, the market demand for hospital acquired infections therapeutics is bound to rise. Market participants such as Merck, Abbott Laboratories, Pfizer Inc., GlaxoSmithKline Plc., Bayer AG, AbbVie Inc., F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company, Limited and Allergan Plc.

Polaris Market Research has segmented the hospital acquired infections therapeutic market report on the basis of drug class, infection type, and region:

Hospital Acquired Infections Therapeutic, Drug Class Outlook (Revenue - USD Million, 2016 - 2028)

Antibacterial Drugs

Cell Wall Synthesis Inhibitors

Protein Synthesis Inhibitors

Others

Antiviral Drugs

Antifungal Drugs

Hospital Acquired Infections Therapeutic, Infection Type Outlook (Revenue - USD Million, 2016 - 2028)

Urinary Tract Infections

Ventilator-associated Pneumonia

Surgical Site Infections

Bloodstream Infections

Other Hospital Infections

Hospital Acquired Infections Therapeutic, by Regional Outlook (Revenue - USD Million, 2016 - 2028)

North America

U.S.

Canada

Europe

France

Germany

UK

Italy

Spain

Netherlands

Austria

Asia Pacific

China

India

Japan

Malaysia

South Korea

Indonesia

Central & South America

Mexico

Brazil

Argentina

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Hospital Acquired Infections Therapeutic Market Insights

  • 4.1. Hospital Acquired Infections Therapeutic - Industry snapshot
  • 4.2. Hospital Acquired Infections Therapeutic Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. High prevalence of hospital acquired infections
      • 4.2.1.2. Cocerned research and innovation
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Antimicrobial resistance
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Hospital Acquired Infections Therapeutic Market Industry trends

5. Hospital Acquired Infections Therapeutic Market Assessment by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • 5.3. Antibacterial Drugs
    • 5.3.1. Global Hospital Acquired Infections Therapeutic Market, by Antibacterial Drugs, by Region, 2016 - 2028 (USD Million)
    • 5.3.2. Cell Wall Synthesis Inhibitors
      • 5.3.2.1. Cell Wall Synthesis Inhibitors Market, by Region, 2016 - 2028 (USD Million)
    • 5.3.3. Protein Synthesis Inhibitors
      • 5.3.3.1. Protein Synthesis Inhibitors Market, by Region, 2016 - 2028 (USD Million)
    • 5.3.4. Others
      • 5.3.4.1. Others Market, by Region, 2016 - 2028 (USD Million)
  • 5.4. Antiviral Drugs
    • 5.4.1. Global Hospital Acquired Infections Therapeutic Market, by Antiviral Drugs, by Region, 2016 - 2028 (USD Million)
  • 5.5. Antifungal Drugs
    • 5.5.1. Global Hospital Acquired Infections Therapeutic Market, by Antifungal Drugs, by Region, 2016 - 2028 (USD Million)

6. Global Hospital Acquired Infections Therapeutic Market, by Infection Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • 6.3. Urinary Tract Infections
    • 6.3.1. Global Hospital Acquired Infections Therapeutic Market, by Urinary Tract Infections, By Region, 2016 - 2028 (USD Million)
  • 6.4. Ventilator-associated Pneumonia
    • 6.4.1. Global Hospital Acquired Infections Therapeutic Market, by Ventilator-associated Pneumonia, by Region, 2016 - 2028 (USD Million)
  • 6.5. Surgical Site Infections
    • 6.5.1. Global Hospital Acquired Infections Therapeutic Market, by Surgical Site Infections, by Region, 2016 - 2028 (USD Million)
  • 6.6. Bloodstream Infections
    • 6.6.1. Global Hospital Acquired Infections Therapeutic Market, by Bloodstream Infections, by Region, 2016 - 2028 (USD Million)
  • 6.7. Other Hospital Infections
    • 6.7.1. Global Hospital Acquired Infections Therapeutic Market, by Other Hospital Infections, by Region, 2016 - 2028 (USD Million)

7. Hospital Acquired Infections Therapeutic Market Assessment by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Hospital Acquired Infections Therapeutic Market Assessment, By Geography, 2016 - 2028 (USD Million)
  • 7.3. Hospital Acquired Infections Therapeutic Market - North America
    • 7.3.1. North America: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
    • 7.3.2. North America: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.3.3. Hospital Acquired Infections Therapeutic Market - U.S.
      • 7.3.3.1. U.S.: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.3.3.2. U.S.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.3.4. Hospital Acquired Infections Therapeutic Market - Canada
      • 7.3.4.1. Canada: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.3.4.2. Canada.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • 7.4. Hospital Acquired Infections Therapeutic Market - Europe
    • 7.4.1. Europe: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
    • 7.4.2. Europe: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.3. Hospital Acquired Infections Therapeutic Market - UK
      • 7.4.3.1. UK: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.3.2. UK: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.4. Hospital Acquired Infections Therapeutic Market - France
      • 7.4.4.1. France: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.4.2. France: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.5. Hospital Acquired Infections Therapeutic Market - Germany
      • 7.4.5.1. Germany: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.5.2. Germany: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.6. Hospital Acquired Infections Therapeutic Market - Italy
      • 7.4.6.1. Italy: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.6.2. Italy: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.7. Hospital Acquired Infections Therapeutic Market - Spain
      • 7.4.7.1. Spain: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.7.2. Spain: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.8. Hospital Acquired Infections Therapeutic Market - Netherlands
      • 7.4.8.1. Netherlands: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.8.2. Netherlands: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.4.9. Hospital Acquired Infections Therapeutic Market - Austria
      • 7.4.9.1. Austria: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.4.9.2. Austria: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • 7.5. Hospital Acquired Infections Therapeutic Market - Asia-Pacific
    • 7.5.1. Asia Pacific: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
    • 7.5.2. Asia Pacific: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.5.3. Hospital Acquired Infections Therapeutic Market - China
      • 7.5.3.1. China: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.5.3.2. China: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.5.4. Hospital Acquired Infections Therapeutic Market - India
      • 7.5.4.1. India: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.5.4.2. India.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.5.5. Hospital Acquired Infections Therapeutic Market - Malaysia
      • 7.5.5.1. Malaysia: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.5.5.2. Malaysia: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.5.6. Hospital Acquired Infections Therapeutic Market - Japan
      • 7.5.6.1. Japan: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.5.6.2. Japan: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.5.7. Hospital Acquired Infections Therapeutic Market - Indonesia
      • 7.5.7.1. Indonesia: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.5.7.2. Indonesia: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.5.8. Hospital Acquired Infections Therapeutic Market - South Korea
      • 7.5.8.1. South Korea: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.5.8.2. South Korea.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • 7.6. Hospital Acquired Infections Therapeutic Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
    • 7.6.2. Middle East & Africa.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.6.3. Hospital Acquired Infections Therapeutic Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.6.3.2. Saudi Arabia.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.6.4. Hospital Acquired Infections Therapeutic Market - UAE
      • 7.6.4.1. UAE: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.6.4.2. UAE: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.6.5. Hospital Acquired Infections Therapeutic Market - Israel
      • 7.6.5.1. Israel: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.6.5.2. Israel: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.6.6. Hospital Acquired Infections Therapeutic Market - South Africa
      • 7.6.6.1. South Africa: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.6.6.2. South Africa: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • 7.7. Hospital Acquired Infections Therapeutic Market - Latin America
    • 7.7.1. Latin America: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
    • 7.7.2. Latin America: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.7.3. Hospital Acquired Infections Therapeutic Market - Mexico
      • 7.7.3.1. Mexico: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.7.3.2. Mexico.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.7.4. Hospital Acquired Infections Therapeutic Market - Brazil
      • 7.7.4.1. Brazil: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.7.4.2. Brazil.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
    • 7.7.5. Hospital Acquired Infections Therapeutic Market - Argentina
      • 7.7.5.1. Argentina: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
      • 7.7.5.2. Argentina.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisition
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Merck & Co., Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Prooduct Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Pfizer Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Prooduct Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Bayer AG
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Prooduct Benchmarking
    • 9.3.4. Recent Development
  • 9.4. GlaxoSmithKline Plc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Prooduct Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Daiichi Sankyo Company, Limited
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Prooduct Benchmarking
    • 9.5.4. Recent Development
  • 9.6. AbbVie Inc.
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Prooduct Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Abbott Laboratories
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Prooduct Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Allergan Plc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Prooduct Benchmarking
    • 9.8.4. Recent Development
  • 9.9. F. Hoffmann-La Roche Ltd
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Prooduct Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Basilea Pharmaceutica AG
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Prooduct Benchmarking
    • 9.10.4. Recent Development

List of Tables

  • Table 1 Global Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 2 Global Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 3 Hospital Acquired Infections Therapeutic Market Assessment, By Geography, 2016 - 2028 (USD Million)
  • Table 4 North America: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 5 North America: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 6 U.S.: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 7 U.S.: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 8 Canada: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 9 Canada: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 10 Europe: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 11 Europe: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 12 UK: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 13 UK: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 14 France: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 15 France: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 16 Germany: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 17 Germany: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 18 Italy: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 19 Italy: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 20 Spain: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 21 Spain: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 22 Netherlands: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 23 Netherlands: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 24 Austria: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 25 Austria: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 26 Asia Pacific: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 27 Asia Pacific: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 28 China: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 29 China: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 30 India: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 31 India: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 32 Malaysia: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 33 Malaysia: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 34 Japan: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 35 Japan: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 36 Indonesia: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 37 Indonesia: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 38 South Korea: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 39 South Korea: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 40 Middle East & Africa: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 41 Middle East & Africa: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 42 Saudi Arabia: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 43 Saudi Arabia: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 44 UAE: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 45 UAE: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 46 Israel: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 47 Israel: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 48 South Africa: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 49 South Africa: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 50 Latin America: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 51 Latin America: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 52 Mexico: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 53 Mexico: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 54 Brazil: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 55 Brazil: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)
  • Table 56 Argentina: Hospital Acquired Infections Therapeutic Market, By Drug Class, 2016 - 2028 (USD Million)
  • Table 57 Argentina: Hospital Acquired Infections Therapeutic Market, By Infection Type, 2016 - 2028 (USD Million)

List of Figures

Figure 1 Market Highlights (2020, Revenue)

Figure 2 Integrated Ecosystem

Figure 3 Research Methodology: Top Down & Bottom Up Approach

Figure 4 Market by Geography

Figure 5 Porter's Five Forces

Figure 6 Market by Drug Class

Figure 7 Global Hospital Acquired Infections Therapeutic Market, By Drug Class, 2020 & 2028 (USD Million)

Figure 8 Market by Infection Type

Figure 9 Global Hospital Acquired Infections Therapeutic Market, By Infection Type, 2020 & 2028 (USD Million)

Figure 10 Hospital Acquired Infections Therapeutic Market Assessment, By Geography, 2016 - 2028 (USD Million)

Figure 11 Strategic Analysis - Hospital Acquired Infections Therapeutic Market